Related Experiment Video
Updated: Jun 23, 2025
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
Published on: March 29, 2024
Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models
Jezabel Rodriguez-Blanco1,2, April D Salvador1, Robert K Suter3
1Darby Children's Research Institute, Department of Pediatrics, and.
Abstract:
Most children with medulloblastoma (MB) achieve remission, but some face very aggressive metastatic tumors. Their dismal outcome highlights the critical need to advance therapeutic approaches that benefit such high-risk patients. Minnelide, a clinically relevant analog of the natural product triptolide, has oncostatic activity in both preclinical and early clinical settings. Despite its efficacy and tolerable toxicity, this compound has not been evaluated in MB. Utilizing a bioinformatic data set that integrates cellular drug response data with gene expression, we predicted that Group 3 (G3) MB, which has a poor 5-year survival, would be sensitive to triptolide/Minnelide. We subsequently showed that both triptolide and Minnelide attenuate the viability of G3 MB cells ex vivo. Transcriptomic analyses identified MYC signaling, a pathologically relevant driver of G3 MB, as a downstream target of this class of drugs. We validated this MYC dependency in G3 MB cells and showed that triptolide exerts its efficacy by reducing both MYC transcription and MYC protein stability. Importantly, Minnelide acted on MYC to reduce tumor growth and leptomeningeal spread, which resulted in improved survival of G3 MB animal models. Moreover, Minnelide improved the efficacy of adjuvant chemotherapy, further highlighting its potential for the treatment of MYC-driven G3 MB.
Insights
Minnelide shows promise for treating aggressive Group 3 medulloblastoma (MB) in children. This drug targets MYC signaling, reducing tumor growth and improving survival in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Medulloblastoma (MB) is a common childhood brain tumor, with Group 3 (G3) MB exhibiting aggressive behavior and poor prognosis.
- Current therapeutic strategies for high-risk MB patients require advancement due to dismal outcomes.
- Minnelide, a triptolide analog, demonstrates oncostatic activity but has not been evaluated in MB.
Purpose of the Study:
- To investigate the efficacy of triptolide and Minnelide in Group 3 medulloblastoma.
- To identify the molecular mechanisms underlying the anti-tumor activity of these compounds in G3 MB.
- To assess the potential of Minnelide as a therapeutic agent for high-risk G3 MB.
Main Methods:
- Bioinformatic analysis integrating drug response and gene expression data to predict sensitivity.
- Ex vivo assessment of triptolide and Minnelide on G3 MB cell viability.
- Transcriptomic analysis to identify downstream drug targets.
- In vivo studies in G3 MB animal models to evaluate tumor growth, spread, and survival.
- Combination therapy studies with adjuvant chemotherapy.
Main Results:
- Bioinformatic predictions identified G3 MB as sensitive to triptolide/Minnelide.
- Both compounds significantly reduced G3 MB cell viability ex vivo.
- MYC signaling, a key driver of G3 MB, was identified as a downstream target.
- Triptolide reduced MYC transcription and protein stability.
- Minnelide decreased tumor growth and leptomeningeal spread, improving survival in G3 MB models.
- Minnelide enhanced the efficacy of adjuvant chemotherapy.
Conclusions:
- Triptolide and Minnelide exhibit anti-cancer activity against Group 3 medulloblastoma.
- The efficacy of these drugs is mediated through the inhibition of MYC signaling.
- Minnelide demonstrates significant therapeutic potential for high-risk G3 MB, including reducing metastasis and improving survival.
- Minnelide may enhance current chemotherapy regimens for MYC-driven G3 MB.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:10Drugs that Destabilize Microtubules